Table 1 Demographic and medical characteristics of men with prostate cancer on androgen deprivation therapy in Toronto, Ontario, Canada, July 2015–October 2016 (N = 46)
Variable | Mean ± SD or n (%) |
|---|---|
Age | 73.2 ± 7.3 |
Marital Status | |
 Never married | 3 (6.5) |
 Married/common law | 39 (84.8) |
 Widowed | 2 (4.3) |
 Divorced | 2 (4.3) |
Education | |
 Some high school | 4 (8.7) |
 Completed high school | 4 (8.7) |
 Some university/college | 13 (28.3) |
 Completed university/college | 16 (34.8) |
 Some/completed graduate school | 9 (19.5) |
Employment status | |
 Employed full−/part-time | 11 (23.9) |
 Retired | 34 (73.9) |
 Other | 1 (2.2) |
Ethnicity | |
 White | 37 (80.4) |
 Black | 4 (8.7) |
 South Asian | 2 (4.3) |
 Southeast Asian | 1 (2.2) |
 Other | 2 (4.3) |
Body mass index | 28.0 ± 3.0 |
 Healthy weight | 8 (17.4) |
 Overweight | 26 (56.5) |
 Obese | 12 (26.1) |
Number of comorbidities | |
 None | 4 (8.7) |
 1 | 11 (23.9) |
 2 | 14 (30.4) |
  ≥ 3 | 18 (36.9) |
aMost common comorbidities | |
 High blood pressure | 27 (61.4) |
 High cholesterol | 19 (43.2) |
 Arthritis | 15 (34.1) |
Smoking status | |
 Never smoked | 23 (50.0) |
 Ex-smoker | 22 (47.8) |
 Regular smoker | 1 (2.2) |
Alcohol consumption | |
 Never | 8 (17.4) |
 Less than once a month | 7 (15.2) |
 2–3 times a month | 5 (10.9) |
 Once a week | 4 (8.7) |
 2–3 times a week | 6 (13.0) |
 4–6 times a week | 8 (17.4) |
 Every day | 8 (17.4) |
Months since diagnosis | 93.6 ± 71.2 |
Disease stage | |
 Localized | 30 (65.2) |
 Metastatic | 15 (32.6) |
 Unsure | 1 (2.2) |
Androgen deprivation therapy administration | |
 Continuous | 29 (63.0) |
 Intermittent | 15 (32.6) |
 Unsure | 2 (4.3) |
aCurrent/prior prostate cancer treatment | |
 Surgery | 25 (54.3) |
 Radiation | 38 (82.6) |
 Chemotherapy | 3 (6.5) |
Current treatment status | |
 Completed treatment | 19 (41.3) |
 Receiving treatment | 27 (58.7) |
Cancer disease recurrence | |
 Yes | 16 (34.8) |
 No | 30 (65.2) |
Current cancer disease status | |
 Disease-free | 15 (32.6) |
 Existing disease | 31 (67.4) |